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Skin is the most immunogenic component of a vascularized composite allograft (VCA) and is the primary trigger and target of
rejection. The skin is directly accessible for visual monitoring of acute rejection (AR) and for directed biopsy, timely therapeutic
intervention, and management of AR. Logically, antirejection drugs, biologics, or other agents delivered locally to the VCA may
reduce the need for systemic immunosuppression with its adverse effects. Topical FK 506 (tacrolimus) and steroids have been
used in clinical VCA as an adjunct to systemic therapy with unclear beneficial effects. However, there are no commercially
available topical formulations for other widely used systemic immunosuppressive drugs such as mycophenolic acid, sirolimus, and
everolimus. Investigating the site-specific therapeutic effects and efficacy of systemically active agents may enable optimizing the
dosing, frequency, and duration of overall immunosuppression inVCAwithminimization or elimination of long-termdrug-related
toxicity.
1. Introduction
Since 1998,more than 200 patients have received vascularized
composite allografts (VCAs). VCAs such as hand, face, or
abdominal wall transplants are unique from solid organ
transplants (SOTs) because of their heterogenous tissue com-
position thatmay include skin,muscle, vessels, tendon, nerve,
lymph nodes, cartilage, bone, and bonemarrow. Importantly,
skin has been shown to be themost immunogenic constituent
of certainVCA [1]mandating long-term immunosuppression
for graft survival. However, transplantation of a whole limb
allograft interestingly elicits a lower immune response than
transplantation of individual tissue components, such as skin
in the form of vascularized or nonvascularized grafts [1].
Despite evolving clinical experience and progress in the
understanding of the biology of VCA, one of the main factors
preventing wider acceptance or routine clinical application
is the associated adverse effects of long-term immunosup-
pression. Antirejection therapy can lead to diabetes melli-
tus, nephrotoxicity, osteonecrosis, leukopenia, hypertension,
hyperlipidemia, and opportunistic bacterial and viral infec-
tions [2, 3]. Since VCAs are non-life-saving procedures, the
risks and toxicity of immunosuppression must be carefully
balanced against their potential life enhancing benefits in
recipients.
Unlike most SOTs, VCAs offer unique opportunities for
local delivery of immunosuppressive medications directly
to the graft. The rationale for such site-specific, transplant-
targeted delivery of immunosuppression is to reduce systemic
exposure and global collateral or end-organ adverse effects.
Hypothetically, site-specific graft immunosuppression could
facilitate minimization of overall dosing, frequency, and
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duration of systemic immunosuppression and also help
reduce the number of systemic drugs required for desired
efficacy and improved graft survival.
Like in SOT, noncompliance with immunosuppressive
medication is emerging as an imminent threat to long-
term graft survival in clinical VCA. There has been at least
one report of a VCA loss (1 hand has been explanted)
due to confirmed medication noncompliance [4]. It may
be argued that reducing the overall number or frequency
of administration of systemic agents for graft maintenance
by adjunctive use of site-specific graft immunosuppression
may improve compliance with oral medications. The VCA
graft is the trigger and the target of the recipient immune
response. Advances in systemic immunosuppression have
been based on insights into key pathways in donor or recip-
ient allorecognition including adaptive or innate responses.
Based on the specific cellular and molecular targets and
mechanisms of action of various immunosuppressive agents,
it may be expected that different agents (used topically
or systemically) affect different pathways, components, or
cascades of the immune response after VCA. In some cases,
thismay result inmore specific immunosuppression, whereas
in others it may result in diversion of the immune response
from the allograft while preserving systemic immunity. Such
innovation in maintenance immunosuppression has resulted
in dramatic reductions in AR and improvement in short- and
long-term patient and graft outcomes in SOT. Although true
tolerance is still a holy grail, the reduction or elimination
of some immunosuppressive agents as part of multidrug
regimens with their long-term toxicities is a potential near
term achievable goal. Such a goal could be realized in VCA
by graft delivered therapies used adjunctively with systemic
drugs. Site-specific delivery of agents that individually and
selectively inhibit the immune trigger processes such as
APC activation, T-cell priming, B-cell help, transendothelial
migration of activated T or B cells, and regional lymph nodal
mechanisms including early or ongoing antigen presentation
could enable reductions in need for systemic immunosup-
pression by complementary, synergistic, or additive effects.
Local agentsmay also prevent ischemia-reperfusion injury, in
which leukocyte-endothelial cell interactions (as in rejection)
are thought to play a key role. Optimal graft tissue con-
centrations/bioavailability of locally delivered drugs (mono
or combination therapy) may indeed allow rejection control
with lower systemic troughs compared to similar antirejec-
tion efficacy with higher overall systemic troughs secondary
to mono- or multidrug maintenance therapy.
2. Route of Application
Several strategies exist for local delivery of immunosup-
pressive/immunomodulatory therapies in VCAs: (1) topical
therapies are applied to the surface of the skin but do not
effectively overcome the skin barrier, for example, therapies
for psoriasis or atopic dermatitis; (2) transdermal therapies
such as patches are more successful in overcoming the skin
barrier and promote a local or systemic effect; (3) subcuta-
neous or intradermal (e.g., insulin injection, TB vaccination);
and (4) intravascular delivery of the immunosuppressive
drugs directly into the transplanted allograft [5]. In VCA,
all of these strategies might be of potential interest and of
significant relevance, depending on the immunosuppressive
regimen and the predicated clinical situation. They can
be also considered as adjunct or alternative to systemic
treatment [6].
It may be a challenge to distinguish the unique effects of
topical versus transdermal therapy. In certain cases, topical
delivery can result in systemic levels that are higher or lower
than expected. Topical calcineurin inhibitors and glucocorti-
coids have been the focus of several such studies. However,
conclusions from these and other similar studies are limited
by confounding effects of increased systemic absorption of
the locally applied agents (due to locally inflamed or abraded
skin) or failure to routinely monitor blood levels or the drug
toxicity [7]. In studies with topical cyclosporine, low systemic
levels have been reported [8].
2.1. Topical Therapy. The classical formulations used for
topical therapy are ointments, cre`mes, lotions, gels, and
powders, which are widely used in the treatment of der-
matological disorders. Topical calcineurin inhibitors were
initially developed for the treatment of atopic dermatitis [9].
FDA-approved commercial formulations available include
tacrolimus (Protopic), which is available as an ointment,
pimecrolimus (Elidel), which is a cream, and clobetasol
propionate, which is also a cream. Different reports suggest a
beneficial effect in conditions such as seborrheic dermatitis,
vitiligo, atopic dermatitis, lichen planus, or psoriasis [10–12].
Sirolimus (rapamycin) is a macrolide antibiotic, struc-
turally similar to tacrolimus. It binds to FKBP-12 and affects
the G
1
phase of the cell cycle by acting on a unique cellular
target called mammalian target of rapamycin (mTOR) [13].
Sirolimus has been mainly used systemically in SOT, but
topical treatment has also been reported in an experimen-
tal/preclinical setting in dermatology. It has been shown to
have beneficial effects in conditions such as facial angiofibro-
mas, psoriasis, and lichen planus, with either undetectable or
insignificant blood levels [14–16]. Sirolimus lotion [16] has
been used in oral lichen planus.
Mycophenolatemofetil (MMF) is an ester ofmycopheno-
lic acid (MPA). It selectively blocks proliferation of T cells and
suppresses antibody formation by B cells [17]. There is only
limited data that is available on topical MPA. Different MMF
formulations as eye drop solutions and aqueous suspensions
have been evaluated. In a corneal allograftmodel topicalMPA
showed no significant difference compared to vehicle only or
no treatment [18]. However, Shoji et al. showed that topical
MPA may be effective in an experimental model of allergic
contact dermatitis [19]. None of the above-mentioned agents
have been systematically evaluated as a topical therapy for
VCA.
2.2. Transdermal Therapy. Transdermal patches that have
been used for the delivery of drugs include but are not limited
to nicotine, nitroglycerin, fentanyl, or estrogen. Different
methods to optimize systemic exposure of other drugs have
also been described. Prausnitz and Langer [20] proposed
a categorization of transdermal delivery systems into three
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generations: first-generation transdermal delivery systems
are used for the delivery of small, lipophilic, low-dose drugs
and have been clinically implemented [20]. Drug transport
relies on diffusion through the stratum corneum and the epi-
dermis into the dermis. Second-generation delivery systems
increase skin permeability and driving forces to improve sys-
temic delivery. Different methods have been introduced such
as chemical enhancement [21], noncavitational ultrasound
and iontophoresis [22]. Third-generation delivery systems
rely on disruption of the stratum corneum and include
combinations of chemical enhancers, biochemical enhancers,
transfollicular strategies, microneedles [23], thermal abla-
tion, microdermabrasion, laser electroporation (micropo-
ration), and cavitational ultrasound [20]. In this context
numerous different patents have also been reported. To our
knowledge, none of these novel methods of transdermal
application have been evaluated either in translationalmodels
or clinical settings involving VCA.
2.3. Intradermal/Subcutaneous Injections. Several agents
(drugs, antibodies) have been evaluated in dermatology
for therapeutic efficacy via the intradermal/subcutaneous
administration. The intradermal route is the preferred route
for some vaccinations (such as BCG), while subcutaneous
delivery is superior for some therapies (such as insulin).
Efomycine M is a novel small molecule that blocks E- and
P-selectin [24]. It has shown therapeutic efficacy in mouse
models of psoriasis [25]. Hautz et al. could significantly
prolong hind limb allograft survival in rats with weekly
subcutaneous injections of efomycine M with short-course
systemic antilymphocyte serum (ALS) and tacrolimus
[24]. Local intragraft delivery of other leucocyte migration
blockers such as anti-ICAM-1, anti-LFA-1, and the fibrin
derivative B 𝛽 15–42, which blocks VE-cadherin, has also
been shown to prolong VCA survival with or without
short-course systemic therapy.
2.4. Local Therapy. Local therapy aims at the utilization of
drug administration systems to establish a more selective
delivery of currently available nonspecific immunosuppres-
sive agents directed at the vascular supply of the transplanted
organ/graft through the spatial and temporal control of drug
delivery, for example, via use of catheter delivery or Alzet
miniosmotic pump systems [26].
3. Site-Specific Immunosuppression in
Solid Organ Transplantation
Limited studies have evaluated the application of intravas-
cular administration of immunosuppressive drugs in SOT
[26–28], demonstrating a beneficial outcome of site-specific
immunosuppression by delivering the immunosuppressive
agents directly to the graft. Ruers et al. [29] introduced an
implantable osmoticminipump delivering prednisolone with
an arterial catheter to the renal allograft. Local application
was superior to systemic application at a dosage of 4mg/kg
body weight per day, whereas i.p. or i.v. administration was
ineffective at this dose.
Yano et al. [30] compared the effects of tacrolimus admin-
istered via different routes (hepatic artery, portal vein, and
systemic circulation) in a rat liver allotransplantation model.
In addition to systemic application of tacrolimus (0.08–
1.28mg/kg) for 7 days, a low dose of tacrolimus (0.32mg/kg)
was infused into the hepatic artery or the portal vein for
three days. In contrast to additional infusions of systemic
tacrolimus, local delivery led to dramatically improved allo-
graft outcomes. Further, local delivery of immunosuppres-
sants was superior to systemic delivery in cardiac [31] and
pancreatic islet cell [32] transplantation models.
The lung offers a unique opportunity of directed local
application of drugs, as the highly antigenic airway epithe-
lium of the bronchial/bronchiolar passages is readily acces-
sible for drug delivery. Nebulized cyclosporine delivered via
inhalation to the lung has been used to treat episodes of AR
as well as chronic rejection (CR) in lung transplants at the
University of Pittsburgh.The beneficial effect of local delivery
has also been shownwith aerosolized cyclosporine as a rescue
therapy for refractory AR [33, 34]. A randomized trial over
a two-year period showed lower rates of CR and improved
survival of lung grafts, but no difference in the incidence of
AR [35].
Inhaled cyclosporine is associated with airway irrita-
tion clinically, requiring the addition of lidocaine to the
preparation. Tacrolimus is more potent then cyclosporine,
thus allowing for similar or superior efficacy with twenty
to forty times less drug. Deuse et al. [36] presented a study
aiming at elucidating the mechanism of inhaled tacrolimus
using in vivo and in vitro models. Human airway epithelium
was grown in vitro at an air-liquid interface in order to
simulate inhaled and systemic application of tacrolimus.
The aerosolized tacrolimus was capable of inducing higher
tissue concentrations and lower blood concentrations than
the systemic application of tacrolimus. Concentrations of
tacrolimus in tissue from the trachea and the lung showed
higher peak values after 1 hour if the animals had received
aerosol treatment compared with oral gavage. The peaks,
however, were followed by a rapid decline in tissue drug
concentrations, and 24-hour trough tissue levelswere approx-
imately 2 times lower after TAC inhalation. In vitro IL-
1𝛽 was used to simulate an inflammation similar to AR or
ischemia reperfusion. The inhibitory effects of tacrolimus
on NF-𝜅B phosphorylation and nuclear translocation of
human airway epithelial cells in the presence of IL-1𝛽 could
be clearly demonstrated, and a reduction of inflammatory
cytokine secretion was observed after aerosolized tacrolimus.
Airway epithelium absorbed tacrolimus from the aerosol
and enabled effective inhibition of subepithelial lymphocyte
activation.
To our knowledge, there is only one report of intra-
arterial administration of immunosuppressive drugs in
humans. Furtado et al. [37] reported two patients who
received local immunosuppression. The first patient suffered
a small bowel rejection after combined liver and small bowel
transplantation. At 3 months after the initial transplantation
a second small bowel transplant was performed from a
cadaveric ABO identical, two-HLA-match donor. A 15 cm
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segment of the middle colic artery was isolated in continuity
with the superior mesenteric artery, allowing insertion of
a catheter. The immunosuppressive treatment consisted of
methylprednisolone and tacrolimus (0.12–0.06mg/kg per
day) via catheter for 3 weeks. The second patient received
a small bowel transplant from a cadaveric ABO-identical,
total HLA-mismatched donor. The catheter was inserted in
the same way as mentioned into the middle colic artery and
maintained for 7 weeks. Two major episodes of acute cellular
rejections were treated with 250mg boluses of methylpred-
nisolone and elevated doses of tacrolimus (dosage 0.08–
0.02mg/kg per day). Both patients could be discharged from
the hospital and continue work and education. These two
cases illustrate that in very critical patients local intraarterial
immunosuppressive treatment is feasible.
4. Site-Specific Immunosuppression in VCA
The skin is the largest organ in the body [1, 38] and is
a physical and immunological barrier [39, 40]. It is the
most immunogenic component of a VCA [1]. In hand trans-
plantation the early signs of clinical rejection are seen in
the skin. Pathologically, this may correlate with differential
degrees of cellular infiltrates in the epidermal-dermal or
adnexal structures as classified by the Banff system for VCA.
[41, 42]. The phenomenon of “split tolerance” is associated
with indefinite survival of the musculoskeletal portion, but
rejection of the epidermis of VCA and has been reported in
animal models [43]. It seems to be logical therefore to locally
target the skin and avoid high degree of overall systemic
immunosuppression [44]. However, the cumulative experi-
ence on the use of graft-delivered therapies in clinical VCA
such as hand or face transplants is varied and inconsistent,
leading to debate on the practical utility of such strategies.
Over 90 upper extremities and 20 face transplantations
have been performed worldwide in the past decade [45].
Most AR episodes have been amenable to bolus systemic
steroids, changes to systemic immunosuppression with or
without interventions such as extracorporeal phototherapy
and topical tacrolimus ointment, and/or steroid (clobetasol)
creams used PRN as adjunctive therapy [45]. In hand trans-
plantation, there have been reports of topical tacrolimus and
clobetasol resulting in adequate to complete response during
Banff Grade 1 and 1-2 rejection episodes [46]. Despite their
frequent use, the efficacy of local immunosuppression cur-
rently remains unproven in clinical VCA, due to the challenge
of designing carefully controlled studies or implementation
of such treatment per established protocols that rely on
clinicopathologic correlation [47].
In preclinical studies, topical tacrolimus has been shown
to prolong graft survival in hind limb allotransplantation
models as well as in face transplantation models [7, 48]. Top-
ical tacrolimus did not lead to elevated blood concentrations,
but a 100-fold higher concentration of the drug was observed
in the skin versus underlying tissues [8]. Compared to topical
steroids, which can result in collagen atrophy and skin thin-
ning, tacrolimus has few local adverse effects [49]. Compared
to cyclosporine, which has also been evaluated in topical
treatment, tacrolimus has been shown to have superior effect
due to its higher potency. Different mechanisms of action
of topical tacrolimus and pimecrolimus have been suggested
in the literature. There may be a depletion of inflammatory
dendritic epidermal cells [50], or a reduction of costimulatory
molecules on dendritic cells and alteration of their function
[51, 52]. Additional mechanisms include apoptosis-induced
depletion of T cells [53] and reduced expression of adhesion
molecules [54].
Shirbacheh et al. [55–57] were the first to describe intraar-
terial delivery of immunosuppressive drugs in VCA. These
pioneering studies involved calcineurin inhibitors in an
experimental large animalVCA limb transplantmodel to cor-
relate tissue and local pharmacokinetics with systemic trough
levels and adverse effects [55, 58]. The conclusion was that
tacrolimus is pharmacokinetically inferior to cyclosporine.
Despite its demonstrated efficacy in experimental and clinical
transplantation, our Findings suggest tacrolimus would not
be an appropriate immunosuppressant to be delivered via the
i.a. route for prevention of limb allograft rejection.
The monitoring of a clinical VCA such as a hand or
face transplant has conventionally relied on protocol skin
biopsies and those biopsies mandated by clinical signs of
rejection. Deeper tissues (muscle, nerve, vessel and bone)
have not been biopsied on a regular basis in VCA. Based on
these paradigms, there are several questions that remain to be
answered in VCA that could impact the overall relevance of
topical immunosuppression in VCA.
(1) What are the temporal kinetics and dynamics of
rejection of the various tissue components of VCA
after transplantation?
(2) Is clinical and histopathologic resolution of rejection
in skin (upon systemic or topical intervention) asso-
ciated with similar outcome in underlying tissues?
(3) Is continuous topical treatment superior to systemic
therapy by augmenting local tissue concentrations at
the trigger site of the immune response?
5. Development of New Topical Formulations:
Promise and Potential
Tacrolimus and clobetasol are available for topical adminis-
tration as they are commercially available with FDA approval
for other indications. Other immunosuppressive drugs do
have applications in dermatology and have only been used
systemically, or in experimental skin formulations. With the
intention to develop new immunosuppressive formulations,
we started an in vitro study comparing novel formulations
of topical MPA and sirolimus to commercially available
tacrolimus and clobetasol preparations. Our goal was to
evaluate the local release, tissue bioavailability, and phar-
macokinetics of these immunosuppressive drugs. For the in
vitro studies, a semipermeablemembrane simulating the skin
barrier was used in Franz Diffusion Cells. Preliminary results
showed that less than 10% of the original dose of tacrolimus
penetrates the membrane. In contrast, approximately 10% of
the initial dose of sirolimus diffuses across the membrane.
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With MPA, 38% of the initial applied dose diffuses into the
recipient compartment. This diffusion was time dependent
and continued to occur past 24 hrs. Based on in vitro data,
we hypothesize that if used at the right dosing and frequency,
both sirolimus and tacrolimus could achieve good local
concentrations in the skin, with lower levels in deeper tissues
and minimal systemic drug exposure. MPA on the other
hand appears to have the greatest potential for diffusion
across the membrane in vitro. This suggests that topical
application of MPA will result in higher concentrations of
the drug in muscle and other local sites with possibly some
increase in systemic concentrations as well. Controlling the
concentration of MPA in the formulation and alterations in
the frequency of dosing could further minimize systemic
drug exposure after topical application of MPA.
6. Conclusion
Graft-targeted and delivered site-specific immunosuppres-
sion is uniquely suited for VCA due to direct accessibility
to such interventions. Local graft manipulation with targeted
preloading of immunosuppression may also have potential
benefit in supplementing or reducing the intensity of systemic
induction therapy. Such a strategy may be customized to
deliver high or sustained concentrations of drugs, antibodies,
biologics, and other molecules, which may not be feasible
via the systemic route due to short half-life, inactivation due
to first pass hepatic metabolism, or enzymatic degradation.
The additive, adjuvant, complementary, or synergistic role
of locally administered immunosuppression in conjunction
with systemic delivery cannot be underestimated in VCA
with their accessible cutaneous or mucosal components
amenable to such innovative delivery techniques. The min-
imization of need for multiple drugs, and their dosing, fre-
quency, and duration of treatment with concomitant toxicity
of such systemic therapy by site-specific therapies needs
further investigation and collaborative inquiry especially in
VCA which are not life-saving grafts such as SOT, but life-
enhancing procedures. Potentially, targeting distinct mech-
anistic pathways and molecular targets in the skin immune
systemwith combination of site-specific immunosuppression
may facilitate an immunomodulatory environment that may
indeed induce a permissive milieu for the development of
tolerant VCA.
Acknowledgment
J. T. Schnider is recipient of a Fellowship from the Swiss
National Science Foundation.
References
[1] W. P. A. Lee, M. J. Yaremchuk, Y. C. Pan, M. A. Randolph, C. M.
Tan, andA. J.Weiland, “Relative antigenicity of components of a
vascularized limb allograft,” Plastic and Reconstructive Surgery,
vol. 87, no. 3, pp. 401–411, 1991.
[2] S. Schneeberger, S. Lucchina, M. Lanzetta et al., “Cytomega-
lovirus-related complications in human hand transplantation,”
Transplantation, vol. 80, no. 4, pp. 441–447, 2005.
[3] M. Lanzetta, P. Petruzzo, R. Margreiter et al., “The international
registry on hand and composite tissue transplantation,” Trans-
plantation, vol. 79, no. 9, pp. 1210–1214, 2005.
[4] W. C. Breidenbach, G. R. Tobin, V. S. Gorantla, R. N. Gonzalez,
and D. K. Granger, “A position statement in support of hand
transplantation,” Journal of Hand Surgery, vol. 27, no. 5, pp. 760–
770, 2002.
[5] S. A. Gruber, M. V. Shirbacheh, J. W. Jones, J. H. Barker, and
W. C. Breidenbach, “Local drug delivery to composite tissue
allografts.,”Microsurgery, vol. 20, no. 8, pp. 407–411, 2000.
[6] V. S. Gorantla, G. Brandacher, S. Schneeberger et al., “Favoring
the risk-benefit balance for upper extremity transplantation—
the Pittsburgh Protocol,”HandClinics, vol. 27, no. 4, pp. 511–520,
2011.
[7] M. G. Solari, K. M.Washington, J. M. Sacks et al., “Daily topical
tacrolimus therapy prevents skin rejection in a rodent hind limb
allograftmodel,” Plastic and Reconstructive Surgery, vol. 123, no.
2, supplement, pp. 17S–25S, 2009.
[8] K. S. Black, D. K. Nguyen, C. M. Proctor, M. P. Patel, and C. W.
Hewitt, “Site-specific suppression of cell-mediated immunity by
cyclosporine,” Journal of Investigative Dermatology, vol. 94, no.
5, pp. 644–648, 1990.
[9] T. Luger and C. Paul, “Potential new indications of topical
calcineurin inhibitors,” Dermatology, vol. 215, no. 1, pp. 45–54,
2007.
[10] C. U. Ang-Tiu, C. F. Meghrajani, and C. C. Maano, “Pimecro-
limus 1% cream for the treatment of seborrheic dermatitis: a sys-
tematic review of randomized controlled trials,” Expert Review
of Clinical Pharmacology, vol. 5, no. 1, pp. 91–97, 2012.
[11] C. McCaughey, M. Machan, R. Bennett, J. J. Zone, and C. M.
Hull, “Pimecrolimus 1% cream for oral erosive lichen planus:
a 6-week randomized, double-blind, vehicle-controlled study
with a 6-week open-label extension to assess efficacy and safety,”
Journal of the European Academy of Dermatology and Vene-
reology, vol. 25, no. 9, pp. 1061–1067, 2010.
[12] M. Lebwohl, A. K. Freeman, M. S. Chapman, S. R. Feldman,
J. E. Hartle, and A. Henning, “Tacrolimus ointment is effective
for facial and intertriginous psoriasis,” Journal of the American
Academy of Dermatology, vol. 51, no. 5, pp. 723–730, 2004.
[13] V. S. Gorantla, J. H. Barker, J.W. Jones, K. Prabhune, C.Maldon-
ado, and D. K. Granger, “Immunosuppressive agents in trans-
plantation: mechanisms of action and current anti-rejection
strategies,”Microsurgery, vol. 20, no. 8, pp. 420–429, 2000.
[14] T. Truchuelo, B. Dı´az-Ley, L. Rı´os, J. Alca´ntara, and P. Jae´n,
“Facial angiofibromas treated with topical rapamycin: an excel-
lent choice with fast response,”Dermatology Online Journal, vol.
18, no. 1, p. 15, 2012.
[15] A. D. Ormerod, S. A. A. Shah, P. Copeland, G. Omar, and
A. Winfield, “Treatment of psoriasis with topical sirolimus:
preclinical development and a randomized, double-blind trial,”
British Journal of Dermatology, vol. 152, no. 4, pp. 758–764, 2005.
[16] A. Soria, S. Agbo-Godeau, A. Ta¨ıeb, and C. France`s, “Treatment
of refractory oral erosive lichen planus with topical rapamycin:
7 Cases,” Dermatology, vol. 218, no. 1, pp. 22–25, 2008.
[17] A. C. Allison and E. M. Eugui, “Immunosuppressive and other
effects of mycophenolic acid and an ester prodrug, mycopheno-
late mofetil,” Immunological Reviews, vol. 136, pp. 5–28, 1993.
[18] E. Bertelmann,M. De Ruijter, N. Gong, S. Knapp, andU. Pleyer,
“Survival of corneal allografts following topical treatment with
the immunomodulatormycophenolatemofetil,”Ophthalmolog-
ica, vol. 224, no. 1, pp. 38–41, 2009.
6 Clinical and Developmental Immunology
[19] Y. Shoji, T. Fukumura, M. Kudo, A. Yanagawa, J. Shimada, and
Y. Mizushima, “Effect of topical preparation of mycophenolic
acid on experimental allergic contact dermatitis of guinea-pigs
induced by dinitrofluorobenzene,” Journal of Pharmacy and
Pharmacology, vol. 46, no. 8, pp. 643–646, 1994.
[20] M. R. Prausnitz and R. Langer, “Transdermal drug delivery,”
Nature Biotechnology, vol. 26, no. 11, pp. 1261–1268, 2008.
[21] A. C. Williams and B. W. Barry, “Penetration enhancers,”
Advanced Drug Delivery Reviews, vol. 56, no. 5, pp. 603–618,
2004.
[22] Y. N. Kalia, A. Naik, J. Garrison, and R. H. Guy, “Iontophoretic
drug delivery,” Advanced Drug Delivery Reviews, vol. 56, no. 5,
pp. 619–658, 2004.
[23] M. R. Prausnitz, “Microneedles for transdermal drug delivery,”
Advanced Drug Delivery Reviews, vol. 56, no. 5, pp. 581–587,
2004.
[24] T.Hautz, B. Zelger, J. Grahammer et al., “Molecularmarkers and
targeted therapy of skin rejection in composite tissue allotra-
nsplantation,” American Journal of Transplantation, vol. 10, no.
5, pp. 1200–1209, 2010.
[25] M. P. Scho¨n, T. Krahn, M. Scho¨n et al., “Efomycine M, a new
specific inhibitor of selectin, impairs leukocyte adhesion and
alleviates cutaneous inflammation,” Nature Medicine, vol. 8, no.
4, pp. 366–372, 2002.
[26] S. A. Gruber, “The case for local immunosuppression,” Trans-
plantation, vol. 54, no. 1, pp. 1–11, 1992.
[27] S. A. Gruber, W. J. M. Hrushesky, R. J. Cipolle et al., “Local
immunosuppression with reduced systemic toxicity in a canine
renal allograft model,” Transplantation, vol. 48, no. 6, pp. 936–
943, 1989.
[28] S. A. Gruber, R. J. Cipolle, D. M. Canafax et al., “An implantable
pump for intrarenal infusion of immunosuppressants in a
canine autotransplant model,” Pharmaceutical Research, vol. 5,
no. 12, pp. 781–785, 1988.
[29] T. J. M. Ruers, W. A. Buurman, and J. F. M. Smits, “Local
treatment of renal allografts, a promising way to reduce the
dosage of immunosuppressive drugs. Comparison of various
ways of administering prednisolone,” Transplantation, vol. 41,
no. 2, pp. 156–161, 1986.
[30] K. Yano, Y. Fukuda, R. Sumimoto, K. Sumimoto, H. Ito, and K.
Dohi, “Suppression of liver allograft rejection by administration
of 15-deoxyspergualin. Comparison of administration via the
hepatic artery, portal vein, or systemic circulation,” Transplant
International, vol. 7, no. 3, pp. 149–156, 1994.
[31] S. M. Stepkowski, S. Goto, T. Ito et al., “Prolongation of het-
erotopic heart allograft survival by local delivery of continuous
low-dose cyclosporine therapy,” Transplantation, vol. 47, no. 1,
pp. 17–23, 1989.
[32] X. Wang, E. J. Alfrey, A. Posselt, L. Tafra, A. M. Alak, and
D. C. Dafoe, “Intraportal delivery of immunosuppression to
intrahepatic islet allograft recipients,” Transplant International,
vol. 8, no. 4, pp. 268–272, 1995.
[33] A. T. Iacono, R. J. Keenan, S. R. Duncan et al., “Aerosolized
cyclosporine in lung recipients with refractory chronic rejec-
tion,” American Journal of Respiratory and Critical Care
Medicine, vol. 153, no. 4, pp. 1451–1455, 1996.
[34] A. T. Iacono, G. C. Smaldone, R. J. Keenan et al., “Dose-related
reversal of acute lung rejection by aerosolized cyclosporine,”
American Journal of Respiratory and Critical Care Medicine, vol.
155, no. 5, pp. 1690–1698, 1997.
[35] A. T. Iacono, B. A. Johnson,W. F. Grgurich et al., “A randomized
trial of inhaled cyclosporine in lung-transplant recipients,”The
New England Journal of Medicine, vol. 354, no. 2, pp. 141–150,
2006.
[36] T. Deuse, F. Blankenberg, M. Haddad et al., “Mechanisms
behind local immunosuppression using inhaled tacrolimus in
preclinical models of lung transplantation,”American Journal of
Respiratory Cell and Molecular Biology, vol. 43, no. 4, pp. 403–
412, 2010.
[37] A. Furtado, R. Perdigoto, F. Oliveira et al., “Local immunosup-
pression in clinical small bowel transplantation (report of two
cases),” TPS, vol. 32, no. 6, pp. 1206–1208, 2000.
[38] G. Swann, “The skin is the body’s largest organ,” Journal of
Visual Communication in Medicine, vol. 33, no. 4, pp. 148–149,
2010.
[39] J. M. Jensen and E. Proksch, “The skin’s barrier,” Giornale Ita-
liana di Dermatologia. Minerva Dermatologica, vol. 144, no. 6,
pp. 689–700, 2009.
[40] J. D. Bos, “The skin as an organ of immunity,”Clinical & Experi-
mental Immunology, vol. 107, pp. 3–5, 1997.
[41] L. C. Cendales, A. D. Kirk, J. M. Moresi, P. Ruiz, and D. E.
Kleiner, “Composite tissue allotransplantation: classification of
clinical acute skin rejection,” Transplantation, vol. 81, no. 3, pp.
418–422, 2006.
[42] J. Kanitakis, D. Jullien, P. Petruzzo et al., “Clinicopathologic
features of graft rejection of the first human hand allograft,”
Transplantation, vol. 76, no. 4, pp. 688–693, 2003.
[43] D. W. Mathes, M. A. Randolph, M. G. Solari et al., “Split
tolerance to a composite tissue allograft in a swine model,”
Transplantation, vol. 75, no. 1, pp. 25–31, 2003.
[44] S. Schneeberger, V. S. Gorantla, T. Hautz, B. Pulikkottil, R. Mar-
greiter, and W. P. A. Lee, “Immunosuppression and rejection in
human hand transplantation,” Transplantation Proceedings, vol.
41, no. 2, pp. 472–475, 2009.
[45] M. Siemionow and C. Ozturk, “Face transplantation,” Journal of
Craniofacial Surgery, vol. 23, no. 1, pp. 254–259, 2012.
[46] K. V. Ravindra, J. F. Buell, C. L. Kaufman et al., “Hand
transplantation in theUnited States: experience with 3 patients,”
Surgery, vol. 144, no. 4, pp. 638–644, 2008.
[47] E.Morelon, J. Kanitakis, and P. Petruzzo, “Immunological issues
in clinical composite tissue allo,” Transplantation, Transplanta-
tion, vol. 93, no. 9, pp. 855–859, 2012.
[48] M. Siemionow and C. Ozturk, “An update on facial transplan-
tation cases performed between 2005 and 2010,” Plastic and
Reconstructive Surgery, vol. 128, no. 6, pp. 707e–720e, 2011.
[49] S. Reitamo, J. Rissanen, A. Remitz et al., “Tacrolimus ointment
does not affect collagen synthesis: results of a single-center
randomized trial,” Journal of Investigative Dermatology, vol. 111,
no. 3, pp. 396–398, 1998.
[50] J. Banchereau and R. M. Steinman, “Dendritic cells and the
control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252,
1998.
[51] A. Wollenberg, S. Sharma, D. Von Bubnoff, E. Geiger, J.
Haberstok, and T. Bieber, “Topical tacrolimus (FK506) leads to
profound phenotypic and functional alterations of epidermal
antigen-presenting dendritic cells in atopic dermatitis,” Journal
of Allergy and Clinical Immunology, vol. 107, no. 3, pp. 519–525,
2001.
[52] A. Panhans-Groß, N. Novak, S. Kraft, and T. Bieber, “Human
epidermal Langerhans’ cells are targets for the immunosup-
pressive macrolide tacrolimus (FK506),” Journal of Allergy and
Clinical Immunology, vol. 107, no. 2, pp. 345–352, 2001.
Clinical and Developmental Immunology 7
[53] W. Hoetzenecker, R. Ecker, T. Kopp, A. Stuetz, G. Stingl, and
A. Elbe-Bu¨rger, “Pimecrolimus leads to an apoptosis-induced
depletion of T cells but not Langerhans cells in patients with
atopic dermatitis,” Journal of Allergy and Clinical Immunology,
vol. 115, no. 6, pp. 1276–1283, 2005.
[54] M. Caproni, D. Torchia, E. Schincaglia et al., “Expression of
cytokines and chemokine receptors in the cutaneous lesions
of erythema multiforme and Stevens-Johnson syndrome/toxic
epidermal necrolysis,” British Journal of Dermatology, vol. 155,
no. 4, pp. 722–728, 2006.
[55] M. V. Shirbacheh, X. Ren, J. W. Jones et al., “Pharmacokinetic
advantage of intra-arterial cyclosporin A delivery to vascularly
isolated rabbit forelimb. I. Model development,” Journal of
Pharmacology andExperimentalTherapeutics, vol. 289, no. 3, pp.
1185–1190, 1999.
[56] M. V. Shirbacheh, T. A. Harralson, J. W. Jones et al., “Phar-
macokinetic advantage of intra-arterial cyclosporin A delivery
to vascularly isolated rabbit forelimb. II. Dose dependence,”
Journal of Pharmacology and Experimental Therapeutics, vol.
289, no. 3, pp. 1191–1195, 1999.
[57] M. V. Shirbacheh, J. W. Jones, T. A. Harralson et al., “Pharma-
cokinetics of intra-arterial delivery of tacrolimus to vascularly
isolated rabbit forelimb,” Journal of Pharmacology and Experi-
mental Therapeutics, vol. 289, no. 3, pp. 1196–1201, 1999.
[58] M. V. Shirbacheh, J. W. Jones, W. C. Breidenbach, S. McCabe,
J. H. Barker, and S. A. Gruber, “The case for local immunosup-
pression in composite tissue allotransplantation,” Transplanta-
tion Proceedings, vol. 30, no. 6, pp. 2739–2742, 1998.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
